Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.

Tetsu Tomonari,Joji Tani,Chikara Ogawa,Akihiro Deguchi,Tomonori Senoh,Akio Moriya,Hiroshi Shibata, Hiroshi Fukuno,Hironori Tanaka,Takahiro Tanaka,Tatsuya Taniguchi,Masahiro Sogabe,Yutaka Kawano, Akihiro Morishita,Koichi Takaguchi,Hiroshi Miyamoto,Yasushi Sato,Tsutomu Masaki,Tetsuji Takayama

Hepatology research : the official journal of the Japan Society of Hepatology（2023）

引用 4|浏览11

暂无评分

摘要

Our study suggests that the efficacy and safety of CAB in real-world clinical practice are comparable to those of the phase III trial (CELESTIAL), and that dose reduction of CAB may be a safer treatment option.

查看译文

关键词

cabozantinib,hepatocellular carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要